Ezetimibe and Atorvastatin Therapy on TCFA

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT02588235

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02588235
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02588235. Randomized; no masking; primary purpose prevention. Start 2015-10 (registry gives no type); primary completion 2017-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ezetimibe and Atorvastatin Therapy on TCFA
Intervention (Drug)
Ezetimibe and Atorvastatin
Intervention (Drug)
Atorvastatin
Lead sponsor
Xijing Hospital (class: other)

Record details

Record id
cardio:ct-nct02588235
Content hash
4b374d74b12229de0ae7ca040d6ed1542908749534fe0a90dc2ef2407a5d3873